PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
Portfolio Pulse from Lara Goldstein
The FDA has accepted PharmaTher Holdings' (OTCQB:PHRRF) new drug application for a racemic ketamine product, KETARX. The goal date for the drug is April 29, 2024. PharmaTher anticipates KETARX’s U.S. commercial launch and the pursuit of international approvals thereafter. The company plans to commercialize KETARX in several dosage forms in the U.S. through its partnership with Vitruvias Therapeutics.
September 27, 2023 | 6:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PharmaTher's new drug application for KETARX has been accepted by the FDA, marking a significant milestone for the company. This could potentially lead to a boost in the company's stock in the short term.
The FDA's acceptance of PharmaTher's new drug application is a significant milestone for the company. This news is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term. Furthermore, the company's plans to commercialize KETARX in the U.S. through its partnership with Vitruvias Therapeutics could also contribute to a positive outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100